Department of Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Surg Today. 2010 Jun;40(6):574-7. doi: 10.1007/s00595-008-4091-1. Epub 2010 May 23.
We report a case of advanced ampullary carcinoma with para-aortic lymph node metastasis, which showed a complete response to S-1. The patient underwent cholecystectomy and Roux-en-Y choledochojejunostomy, and was then given S-1 orally 80 mg daily for 14 days, followed by 7 days of rest. After four cycles of the S-1 chemotherapy, both the tumor and the swollen paraaortic lymph node had completely disappeared. An additional six cycles were given at the request of the patient. No adverse effects were seen during the S-1 chemotherapy, and the patient has been free of the disease for the 27 months since its completion. Thus, S-1 monotherapy may be considered as a chemotherapeutic strategy for unresectable ampullary carcinoma, although large-scale studies will be required to confirm its true efficacy.
我们报告一例晚期壶腹癌伴腹主动脉旁淋巴结转移患者，其对 S-1 完全缓解。患者接受了胆囊切除术和 Roux-en-Y 胆肠吻合术，随后每天口服 S-1 80mg，连用 14 天，然后休息 7 天。在进行了四个周期的 S-1 化疗后，肿瘤和肿大的腹主动脉旁淋巴结完全消失。应患者要求又进行了六个周期的化疗。在 S-1 化疗期间没有观察到不良反应，并且自完成化疗以来，患者已经无病生存了 27 个月。因此，S-1 单药治疗可能被认为是不可切除的壶腹癌的一种化疗策略，尽管需要进行大规模研究来证实其真正的疗效。
